Rifampicin treatment has had a significant impact in countries like Ghana, says Benedict Quao, who leads the National Leprosy Control Programme in Ghana, which is a member of the Global Partnership for Zero Leprosy. “For the first time ever, countries had medical guidelines that could push political leadership to act,” he says.
Visit siteIn partnership with GPZL, ZS is collaborating on a roadmap to develop and implement two leprosy diagnostic tests: One to confirm leprosy in people who show symptoms, and the other to screen families and communities of people affected by leprosy.
Visit siteThe Partnership brought the global leprosy community together in new ways across all three workstreams— country partnerships, research, and resource mobilization and advocacy.
DownloadLeading up to World Leprosy Day on 29 January 2023, we asked members of the global leprosy community to share their perspectives on early diagnosis. We asked: Why is early diagnosis of leprosy so important? Watch the video:
In an editorial published in Leprosy Review, Dr. Paul Saunderson shares outcomes from and reflects on our first research workshop, held in September 2021, and subsequent ILEP conferences which focused on early case detection.
Visit siteGlobal Partnership for Zero Leprosy Leadership Conference in Hyderabad, India – 12 November 2022
DownloadGlobal Partnership for Zero Leprosy Leadership Teleconference – 1 September 2022
DownloadA special report on the state of Buruli ulcer and leprosy in Nigeria features interviews with leaders from the National Leprosy Programme, The Leprosy Mission Nigeria, Damien Foundation Nigeria, the Global Partnership for Zero Leprosy (GPZL), and other partners. GPZL Secretariat director, Bill Gallo, and GPZL Program Manager, Mondie Tharp, discuss the development of Nigeria’s Zero Leprosy Roadmap and Action Plan and the opportunity to end leprosy in Nigeria.
Watch VideoLeprosy reactions involve a flare-up of inflammation in the body caused by complex immunological processes, linked to the remains of dead bacilli in the tissues. Reactions may occur before, during, or after treatment. They do not indicate a failure to control the leprosy infection. Normal antibiotic treatment is not affected, and completed treatment does not need to be restarted if a reaction occurs. Reactions occur in many people with leprosy, perhaps up to 50% of cases in some places, especially in patients with the multibacillary disease. Reactions may occur with obvious symptoms, such as red, swollen skin lesions, pain, muscle weakness, or sensory loss, but may also start insidiously, without any clear symptoms.
ENG ESP FR PORThe Global Partnership For Zero Leprosy, a program of the Task Force for Global Health, submitted a statement to the 73rd World Health Organization (WHO) Regional Committee Meeting for the Western Pacific in October 2022. The statement refers to agenda item 14, “Reaching the unreached.” … Read More >